The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2026 | The potential of dual-targeting CAR-T approaches in R/R LBCL
Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses the potential of dual-targeting CAR T-cell therapy approaches in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), highlighting the emergence of various CD19/CD20 targeted CAR-T constructs, including tandem and bicistronic designs. Dr Iacoboni expresses her excitement about future randomized clinical trials comparing the efficacy of these dual-targeted products with that of conventional CD19-directed CAR-T. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Regarding this dual-targeting approach that zamto-cel presented, so as mentioned, this is a second generation CAR T-cell construct with a 4-1BB co-stimulatory domain targeted, you know, directed towards CD19/CD20 tandem construct. It’s very interesting to see that there’s now a wealth of different CD19/CD20 targeted constructs, many presented at ASH and prior meetings in 2025...
Regarding this dual-targeting approach that zamto-cel presented, so as mentioned, this is a second generation CAR T-cell construct with a 4-1BB co-stimulatory domain targeted, you know, directed towards CD19/CD20 tandem construct. It’s very interesting to see that there’s now a wealth of different CD19/CD20 targeted constructs, many presented at ASH and prior meetings in 2025. So different companies in different ways: bicistronic, tandem, usually, you know, CD19/CD20 directed are presenting, you know, efficacy and toxicity data in single arm clinical trials with these constructs. And I think, you know, it’s going to be a very exciting pathway forward because in the following years, we are going to see randomized clinical trials, head-to-head CAR-T versus CAR-T trials, comparing these dual-targeted CD19/CD20 products with our, let’s call them now conventional CD19-directed, available, commercially available CAR-T constructs, you know, axi-cel cell and liso-cel in the relapse refractory large B-cell lymphoma settings. So looking forward to the results to come.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consulting: Autolus, Bristol-Myers Squibb, Kite/Gilead, Janssen, Miltenyi, Abbvie, MSD, Regeneron. Honoraria: Abbvie, AstraZeneca, BMS, Kite/Gilead, Miltenyi, Sobi, Roche, Lilly. Travel support: Abbvie, AstraZeneca, Kite/Gilead, Miltenyi, Roche.
